Maria T. Millan, President and CEO
Dr. Maria T. Millan is a physician-scientist who has devoted her career to treating and developing innovative solutions for children and adults with debilitating and life-threatening conditions. After receiving her undergraduate degree from Duke University where she first entered the arena of immunology research, she returned to her home in New Jersey where she obtained her M.D. and then went on to complete her surgical training and post-doctoral research in Boston at Harvard Medical School – Beth Israel Deaconess Medical Center. After a transplant surgery fellowship at Stanford University School of Medicine, she began her academic career with a busy pediatric and adult transplant surgery practice focused on technical advancements and optimization of patient outcomes, including the treatment of rare fatal diseases. In parallel, she continued her bench research at Stanford and was promoted within 5 years to Associate Professor and the Director of the Pediatric Organ Transplant Program. She served on multiple leadership teams including the Faculty Senate and the Dean’s faculty committee at Stanford University School of Medicine and served on the Children’s Hospital operations committee and currently serves on the editorial board for Stem Cell Translational Medicine and multiple non-profit boards advancing initiatives in health and in growing the healthcare industry ecosystem in California and beyond. She has published in the areas of cell biology, immunology, and clinical organ transplantation.
With early signals from the science that stem cell and regenerative medicine therapy was the new frontier for medicine, she ventured into the private sector in 2006 to join StemCells, Inc., one of the earliest stem cell organizations and the first to enter into an FDA regulated clinical trial with a stem cell treatment for children with a fatal neurodegenerative disease. Dr. Millan then joined the California Institute for Regenerative Medicine in December 2012 where she led the formation of the Alpha Stem Cell Clinics Network, a network of California medical centers that specialize in rigorous and high quality clinical trials and top tier medical care for patients participating in these trials. This clinical network is now composed of seven medical centers and their affiliated hospitals across California and has supported over 130 clinical trials to date. As a key component of CIRM’s bold 5-year strategic plan launched in 2016, which was designed to accelerate stem cell treatments to patients with unmet medical needs, Dr. Millan led the development of critical infrastructure, including specialized regulatory, preclinical research, manufacturing and clinical operations support for stem cell and regenerative medicine trials. In July 2017, Dr. Millan took on the role as President and CEO of CIRM and she was formally appointed by CIRM’s Board in September 2017. Under her leadership, CIRM continues to drive the mission of accelerating stem cell treatments to patients with unmet medical needs, is on track to achieve its 5-year strategic plan, has now funded a 64 clinical trials and is continuing to grow this robust portfolio of high quality programs by the month. In addition, she led the initiative to partner with the NHLBI to drive the “Cure Sickle Cell” Initiative and this is yielding a robust pipeline of cell and gene therapy projects that are on the way to clinical testing.
Jonathan Thomas, Chairman, Independent Citizens’ Oversight Committee (ICOC)
Jon Thomas is a Co-Founding Partner at Saybrook Capital (“Saybrook”), an investment banking and private equity firm based in Santa Monica, California.
Long interested in the biological sciences, Thomas majored in Biology and History at Yale, where he graduated summa cum laude. As a George C. Marshall Scholar at Oxford, he then earned a PhD with a medical focus in Commonwealth History. He subsequently returned to Yale for a JD at the Yale Law School. While there, Thomas retained an involvement with biology by teaching courses on the legal implications of genetic engineering and the impact of disease on history.
Thomas has a long-standing commitment to patient advocacy. He spent more than 15 years on the Board of the Crippled Children’s Society of Southern California and served as chair for four years. The organization, now called AbilityFirst, assists children with spinal cord injuries and mental disabilities that could be targets of stem cell therapies. Thomas is an Honorary member of the AbilityFirst Board.
Senator Art Torres (Ret.), Vice-Chair
Senator Art Torres (Ret.) was unanimously elected statutory Vice Chair of the Independent Citizens Oversight Committee, the governing Board of the California Institute of Regenerative Medicine (CIRM). He is also Chair of the Governance Committee. He is a colon cancer and osteoarthritis survivor.
Between 1996 and 2009, Torres served as the Chair of the California Democratic Party. He previously served twenty years in the California Legislature, eight as a member of the State Assembly and twelve as a State Senator. Torres chaired the Senate Insurance Committee, Senate Toxics Committee, the Assembly Health Committee, and the Senate Joint Committee on Science and Technology.
He is currently on the Board and Vice Chairman of "One Legacy," an organ transplant foundation in the US headquartered in Los Angeles.
He was recently appointed by the California State Senate to the five member board of Covered California which oversees Obamacare in California. He also serves as a member of the Board of Trustees of the UC Santa Cruz Foundation.
Senator Torres authored the California Clean Water Drinking Act, Proposition 65, and created the sole toxic reporting repository that helps scientists determine environmental and health impacts “a data source that really no one else has on the planet.” On November 18th, 2010 he was sworn in by then Mayor Gavin Newsom, to a four year term on San Francisco’s Public Utilities Commission and later elected as its President before stepping down.
Senator Torres holds a Bachelor's Degree from UC Santa Cruz and a Juris Doctorate degree from UC Davis School of Law. He also served as a John F. Kennedy teaching fellow at Harvard University's John F. Kennedy School of Government.
He previously served as a German Marshall Fund Fellow and was recently appointed as the University of San Francisco Diversity Scholar Visiting Professor.
Maria Bonneville, Vice President of Public Outreach and Board Governance
Maria Bonneville is the Vice President of Public Outreach and Board Governance at CIRM and has been with the agency since 2011. Maria is in charge of a team with a wide range of skills but a common goal, communicating CIRM’s mission to the public through the CIRM website, the blog and social media channels as well as in-person events. She works directly with the CIRM Board to advance CIRM’s mission and to lead the development and coordination of Board policies and procedures. She also works with California state legislators and staff members to keep the public up to date on the full scope of CIRM’s activities.
Before joining CIRM, Maria was the Special Assistant to former Treasurer Bill Lockyer at the California State Treasurer’s office where she represented the Treasurer in state business matters with the state and local government and the business community in the Bay Area. She was also the Northern California Finance Director for the Lockyer Committee and was responsible for fundraising programs for the re-election of California Attorney General Bill Lockyer for Treasurer. Maria also has extensive experience with product development, product marketing, E-commerce, and public relations.
She received a Bachelor of Arts in political sciences from the University of California Berkeley.
Rosa Canet-Avilés, Vice President of Scientific Programs
Rosa Canet-Avilés is the Vice President of Scientific Programs at CIRM and leads a team that actively works towards identifying the most promising basic and early stage research in stem cells and other areas related to regenerative medicine and enabling their success. Under her leadership, the Scientific Programs team manages a portfolio of hundreds of active programs that include basic mechanistic research, discovery, exploratory research, and identification of potential candidates for translational development. Rosa is also responsible for the internal and external collaborative networks and consortia that will result from the early-stage scientific programs managed by this group. Together with the rest of the leadership team, Rosa is responsible for the strategic alignment and connectivity with other CIRM programs (e.g., clinical networks, knowledge and data networks, registries, educational and communication portals) with the ultimate goal of translating all these efforts into cures.
Rosa is a familiar face at the agency, serving as a Science Officer with CIRM from 2008 to 2014. During that time, she helped oversee the development of CIRM’s Translational program, managed a broad portfolio of projects and organized workshops on Parkinson’s Disease and Autism amongst other. She brings nearly two decades of experience developing and leading multi-stakeholder initiatives across biopharma, government and nonprofit organizations. In her recent role as the Director of Strategic Alliances at the Eisai Center for Genetics Guided Dementia Discovery (G2D2), as part of the leadership team at G2D2, Rosa was responsible amongst other for the strategic planning of alliances and external innovation partnerships in the neurobiology business unit. As such, Rosa was instrumental in driving growth to the organization through the identification and management of external innovation opportunities. During the previous 7 years, Rosa was the Director of Neuroscience Research Partnerships at the Foundation for the National Institutes of Health (FNIH), Rosa was responsible for the development and management of the Neuroscience Research Partnership portfolio of projects and programs that includes: the Accelerating Medicines Partnership (AMP) for Alzheimer’s Disease (AMP-AD) 1 and 2, AMP Parkinson’s Disease (AMP-PD), AMP Schizophrenia (AMP SCZ), the Alzheimer’s Disease Neuroimaging Initiative 3 (ADNI3) and the Biomarkers Consortium Neuroscience Steering Committee (BC NSC). Rosa managed different teams in coordination with NIH, FDA, non-profit organizations and industry leaders.
Rosa earned her PhD degree in neuroscience from the School of Medicine at Leeds University, UK. She also holds a BS in organic chemistry from the Central University of Barcelona.
Abla Creasey, Vice President of Therapeutics and Strategic Infrastructure
Abla Creasey is the Vice President of Therapeutics and Strategic Infrastructure. As a previous Associate Director of Therapeutics and most recently, as Sr. Director of Strategic Clinical and Regulatory Infrastructure, Abla has been instrumental in building up CIRM’s clinical portfolio and in working closely with our grantees who attained three of the first 11 RMAT-expedited pathway designations from the FDA. She has worked with the Accelerating Center to launch novel accelerating resources for product development, regulatory strategy and pharmaco-economics. In her current role, Abla will ensure that the therapeutics team will continue to meet their big six strategic goals with integration of critical resources from the Clinical Advisory Panel program, Alpha Clinics and the Accelerating Center.
Abla has broad and extensive experience in science, technology, and pharmaceutical product development. Prior to joining CIRM in 2016, she was at Johnson & Johnson for 12 years. While at Johnson and Johnson, Abla was a Senior Scientific Director in Pharmaceutical Development & Manufacturing Sciences at Janssen and prior to that, she was, an Executive Director, heading drug delivery, pharmacology, analytical characterization, clinical & quality at Advanced Technologies & Regenerative Medicine (ATRM), another J&J company. Prior to ATRM, Abla was Vice President of Biological Sciences at ALZA Corporation, where she headed discovery efforts in formulation, preclinical and oral drug delivery. Before joining ALZA in 2004, Abla held senior-level positions in R&D, clinical development, and regulatory affairs within the biotechnology industry including Chiron Corporation and Cetus Corporation.
Abla received a B.S. in biology from the College of Notre Dame in Belmont California, and earned her Ph.D. in medical microbiology from the University of California, Berkeley. She completed a post-doctoral fellowship at the Stanford University School of Medicine in infectious disease, biochemistry, and immunology.
Kevin Marks, General Counsel
Kevin Marks is CIRM’s General Counsel and is responsible for overseeing CIRM’s Legal and Human Resources Departments as well as other operational areas. In his role, Kevin provides guidance to CIRM’s leadership, the Governing Board, and the entire CIRM team in developing strategies to implement CIRM’s mission.
Kevin joined CIRM in June of 2021 after 14 years at Roche Diagnostics in both the therapeutics and diagnostics areas, serving as Vice President and Head of Legal and Compliance at Roche Molecular Solutions (encompassing molecular diagnostics, tissue diagnostics, and sequencing) and Vice President and General Counsel at Roche Molecular Diagnostics. In these roles, Kevin oversaw a teams in general law, employment law, compliance and intellectual property and managed the business area’s global litigation portfolio, coordinated legal and compliance support for nine sites in the US, Europe and Africa, and directed the acquisition and legal integration of six startup companies. Prior to that, Kevin served in Roche’s pharmaceutical side for 9 years as Vice President, General Counsel at Roche Palo Alto, LLC.
Kevin received his undergraduate AB degree at Lafayette College in International Affairs and Russian and his law degree at Villanova University.
Jennifer Mielnicki Lewis, Director of Grants Management
Jennifer Mielnicki Lewis is the Director of Grants Management at CIRM leading the team that ensures the agency’s award and financial management policies and processes are fair, efficient, consistent and positioned to drive CIRM’s strategic goals. Jennifer joined the grants management team at CIRM in 2016. Her responsibilities include managing a diverse portfolio of grants, overseeing the implementation of infrastructure and database enhancements, interpreting and revising policy, and supporting funding partnerships.
Before joining CIRM, Jennifer was a senior member of the program team at the Stuart Foundation where she made funding recommendations, created grantee communications, and developed system and process enhancements. Jennifer’s experience has focused on operational roles spanning the philanthropic, nonprofit, private and government sectors. She also has knowledge in organizational development, project management, and community outreach.
Jennifer received a Bachelor of Hospitality Administration from Boston University and holds a Master of Public Administration from the University of Illinois at Chicago.
Shyam Patel, Director of Business Development
Shyam Patel is Director of Business Development and is responsible for managing CIRM’s Industry Alliance Program and strategic partnerships. Shyam’s team engages with the biotech industry to create visibility for CIRM’s mission and to facilitate industry partnership and commercialization opportunities for CIRM’s portfolio. Shyam led the expansion of CIRM’s Industry Alliance Program to establish a collaborative network of venture investors, biotech companies and large biopharma partners. He also manages CIRM’s partnerships including the Cure Sickle Cell partnership with NHLBI, iPSC repository partnership with Fujifilm CDI and data sharing collaboration with Chan Zuckerberg Initiative.
Shyam joined CIRM in late 2016, initially as part of Dr. Sambrano’s Portfolio Development & Review team where he managed the application, review and approval processes for Discovery, Translational and Clinical Programs. Prior to CIRM, Shyam was CEO and Chief Science Officer for NanoNerve, Inc., where he and his team developed tissue engineered medical devices for tissue regeneration. He was also on the teaching faculty in Bioengineering at the University of California, Berkeley, where he taught undergraduate and graduate courses in biomaterials, stem cells and tissue engineering and medical device development.
Shyam received a B.S. in Bioengineering from the University of California, Berkeley, and a Ph.D. in Bioengineering from the Universities of California Berkeley & San Francisco.
Gil Sambrano, Vice President of Portfolio Development and Review
Gil is the Vice President of Portfolio Dvelopment and Review and leads the team responsible for selecting the highest quality stem cell-based projects for CIRM funding from Discovery to Clinical programs. His team builds and cultivates a world class team of expert reviewers and directs a rigorous review process through the governing board-appointed Grants Working Group (GWG).
Gil joined CIRM in 2005 as the first Scientific Officer. During his tenure, Gil has contributed to building the vision of CIRM by leading and advancing the scientific review process, constructing grants administration policies, guiding early development of the Grants Management System, and managing the training grant programs. He has been a key point of contact to help applicants and grantees identify appropriate partnering opportunities and navigate the CIRM solicitation and application process. He leads the conduct of GWG review meetings and has been the primary liaison with patient advocate and scientific members of the GWG.
Prior to CIRM, he was an assistant professor in the department of Cellular and Molecular Pharmacology at UCSF. In 2001, Gil took on a notable position to coordinate efforts of the Alliance for Cellular Signaling, a multi-institutional and multi-disciplinary consortium of scientists led by the Nobel laureate, Alfred G. Gilman, whose goal is to understand the basic principles that regulate signal transduction in cells.
His scientific education includes a B.S. in biology from the University of Texas at El Paso and a Ph.D. in biomedical sciences from the University of California, San Diego. Gil trained as a postdoctoral fellow at the Cardiovascular Research Institute at the University of California San Francisco.
Pouneh Simpson, Director of Finance
Pouneh Simpson is the Director of Finance and oversees CIRM’s accounting, budget, procurement, contracts and business services functions. Pouneh manages the strategic financial planning and financial forecasting of expenditures and receipts, including bond proceeds and commercial paper receipts. She reports quarterly to the ICOC and Finance Subcommittee on finance, budgeting and financial planning to ensure that the organization complies with Proposition 14 and all State of California laws and regulations. Pouneh also reports to the Citizens Financial Accountability Oversight Committee on an annual basis on the financial practices and performance of the CIRM.
Pouneh started her state career as a Jesse Unruh Fellow in the State Assembly. Pouneh continued in the Executive Branch first at the Department of Finance and then at various state agencies in the areas of finance and administration. She was the Governor’s Appointee to the California Department of Veterans Affairs as the Chief Financial Officer of the Veterans Homes. She also served as Chief of Administration at the Office of Inspector General and State Personnel Board and Chief Financial officer of the California Prison Industry.
She received a Bachelor of Arts in Sociology and Organizational Studies from the University of California Davis and Master of Public Administration from the University of Southern California.